69成人网

Join

menu

Resources

Breast Cancer

HER2-low/ultralow Breast Cancer Playbook

This Playbook provides practical insights for pathologists and laboratory professionals who are working to improve how they perform HER2 testing in breast cancer and how they are navigating some of the challenges around reporting HER2-low and HER2-ultralow results.

The Playbook provides 1CME/1CMLE

 

HER2-Low and HER2-Ultralow Breast Cancer

A Pathology Pointer Infographic

Accurate classification of HER2 status in breast cancer is essential for determining the most effective treatment strategies. This infographic highlights some key concepts of HER2-low and HER2-ultralow breast cancer.

 

These activities are supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Ki67 Testing

These resources, related to a January 2022 ASCP webinar on Ki67 testing, highlight important and practice-changing developments, such as new clinical data with immediate implications for patient care.

The resources address key educational gaps and controversies related to optimal testing methods, addressing challenges with standardization, interpreting findings, and potential therapeutic implications for patients with HR-positive/HER2-negative early breast cancer to optimize clinical outcomes.

Provided by the 69成人网 in partnership with Clinical Care Options, LLC. This activity is supported by an educational grant from Lilly.

HER2-low Breast Cancer

This downloadable, easily sharable set of slides is intended for pathologists to use to educate colleagues on HER2-low breast cancer. The slides cover the following topics:

  • The science of HER2-low breast cancer
  • Clinical practice guidelines for HER2 testing in patients with breast cancer
  • Emerging therapies designed to treat patients with HER2-low breast cancer

Provided by the 69成人网 in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC. Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.